Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Gold Fields Limited (GFI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Gold Fields LimitedTrade
Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Gold Fields Limited vs Recursion Pharmaceuticals Inc — how do they compare? Gold Fields Limited trades at $40.75 (market cap $36.07B), while Recursion Pharmaceuticals Inc trades at $3.28 (market cap $1.81B). The key difference: Gold Fields Limited is far larger — about 19.9× Recursion Pharmaceuticals Inc's market cap, and Gold Fields Limited pays a 5.76% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

GFIRXRX
Market Cap
$36.07B$1.81B
Sector
Basic MaterialsHealth
52-Week High
$61.52$6.79
52-Week Low
$29.31$2.84
Enterprise Value
$37.51B$1.33B
Dividend Yield
5.76%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Gold Fields Limited

Gold Fields (GFI) trades at $41.06, down slightly by 0.15% today. The stock shows strong fundamentals with robust profitability (40.76% net margin, 52.33% ROE) and attractive valuation (P/E 10.22, EV/EBITDA 5.92). Recent earnings were mixed with one beat and two misses, but 2025 projections indicate significant growth. Technical indicators show a bullish overall signal despite overbought RSI readings. Institutional interest remains strong with recent acquisitions by major funds.

The outlook for GFI appears positive with projected revenue growth to $8.8B and net income of $3.6B in 2025. Analyst consensus targets $52.00 (24% upside) with no sell ratings. Key risks include gold price volatility and operational challenges in mining operations. The combination of strong fundamentals, institutional support, and growth projections supports a constructive view for long-term investors.

Recursion Pharmaceuticals Inc

RXRX trades at $3.29, showing no change in the last session. The stock exhibits a bullish technical signal with moving averages supporting an uptrend, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported a Q2 2026 loss of $0.25 per share, missing estimates, with revenues declining year-over-year. Recent news highlights ongoing investor conferences and partnership advancements, such as Genentech optioning a neuroscience target, but profitability remains a challenge with a net income margin of -961.97% for 2026.

The outlook for RXRX is mixed, with analyst consensus leaning hold (60%) due to high cash burn and unproven commercial scalability. Investment opportunity lies in its AI-driven drug discovery platform and partnerships, but risks include sustained losses, competitive pressures, and reliance on milestone payments. The stock's trajectory hinges on pipeline success and cost management improvements.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Gold Fields Limited

Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.

Read more on GFI

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX